Quantitative Systems Pharmacology: Applications and Adoption in Drug Development

Biopharmaceutical companies have increasingly been exploring Quantitative Systems Pharmacology (QSP) as a potential avenue to address current challenges in drug development. The ability to integrate diverse data into a unified framework provides a promising approach for a systematic, quantitative evaluation and prediction of the complex interaction between potential therapeutics and biological pathways of disease, with application across the research and development pipeline. In this chapter, we discuss the potential for QSP to help address pressing needs in drug development, and present numerous examples of past applications to problems ranging from target identification to in vivo experimental design through clinical trial simulation, patient stratification, and regulatory evaluation. These examples also illustrate the diversity of QSP modeling approaches. Moving forward, the adoption and success of QSP will require a clearly articulated record of impact on drug development decisions, alongside the development of approaches to address current challenges in the implementation and technical evaluation of such efforts.

[1]  SRB Allerheiligen,et al.  Impact of Modeling and Simulation: Myth or Fact? , 2014, Clinical pharmacology and therapeutics.

[2]  K. Boye,et al.  Cardiovascular outcomes associated with a new once‐weekly GLP‐1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis , 2011, Diabetes, obesity & metabolism.

[3]  John D. Davis,et al.  A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.

[4]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[5]  Peter Falkai,et al.  Clozapine alone versus clozapine and risperidone with refractory schizophrenia. , 2006, The New England journal of medicine.

[6]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[7]  Robert P Kocher,et al.  The calculus of cures. , 2014, The New England journal of medicine.

[8]  B. Agoram,et al.  Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models , 2014, CPT: pharmacometrics & systems pharmacology.

[9]  J. Rullmann,et al.  Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. , 2005, Systems biology.

[10]  M. Bullano,et al.  The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model , 2012, ClinicoEconomics and outcomes research : CEOR.

[11]  H. Kitano,et al.  Software for systems biology: from tools to integrated platforms , 2011, Nature Reviews Genetics.

[12]  U. Nielsen,et al.  Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors , 2012, CPT: pharmacometrics & systems pharmacology.

[13]  Albert Wang,et al.  Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..

[14]  Hugh A. Barton,et al.  Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..

[15]  J. Arrowsmith,et al.  A decade of change , 2012, Nature Reviews Drug Discovery.

[16]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[17]  Tanya Cashorali,et al.  Causal Modeling Using Network Ensemble Simulations of Genetic and Gene Expression Data Predicts Genes Involved in Rheumatoid Arthritis , 2011, PLoS Comput. Biol..

[18]  R. Iyengar,et al.  Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics , 2013, Clinical pharmacology and therapeutics.

[19]  M. Riggs,et al.  Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.

[20]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[21]  U. Iloeje,et al.  Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes , 2014, Diabetes, obesity & metabolism.

[22]  H Geerts,et al.  A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia , 2013, CPT: pharmacometrics & systems pharmacology.

[23]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[24]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[25]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[26]  J. Arrowsmith Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[27]  Neil Benson,et al.  Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology , 2013, Interface Focus.

[28]  P. Watkins,et al.  A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial , 2014, CPT: pharmacometrics & systems pharmacology.

[29]  Melvin E. Andersen,et al.  Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches , 2012, Front. Physio..

[30]  Richard Kahn,et al.  Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis , 2009, Diabetes Care.

[31]  Hugo Geerts,et al.  Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[33]  CM Friedrich,et al.  A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.

[34]  Marc R Gastonguay,et al.  Multiscale Physiology‐Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function , 2012, Journal of clinical pharmacology.

[35]  Ravi Iyengar,et al.  Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.

[36]  Fergal P. Casey,et al.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.

[37]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[38]  Matthew M Riggs,et al.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.

[39]  Elisa Binda,et al.  High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. , 2014, Rheumatology.

[40]  L. Kuepfer Towards whole-body systems physiology , 2010, Molecular systems biology.

[41]  P Vicini,et al.  Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? , 2013, Clinical pharmacology and therapeutics.

[42]  Adam Cohen,et al.  Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development , 2008, Clinical pharmacokinetics.

[43]  O Demin,et al.  Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors , 2013, CPT: pharmacometrics & systems pharmacology.

[44]  Jan van den Berg,et al.  Systems Biology and Pharmacology , 2010, Clinical pharmacology and therapeutics.

[45]  P. Roberson,et al.  Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts , 2003, Journal of Biological Chemistry.

[46]  C. Allaart,et al.  Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. , 2011, Arthritis and rheumatism.

[47]  James Lu,et al.  An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway , 2014, PLoS Comput. Biol..

[48]  Christian Sonesson,et al.  Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis , 2016, Cardiovascular Diabetology.

[49]  Gary R. Mirams,et al.  Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.

[50]  B. Hendriks,et al.  Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect , 2013, Molecular Cancer Therapeutics.

[51]  Yoram Rudy,et al.  Rate Dependence and Regulation of Action Potential and Calcium Transient in a Canine Cardiac Ventricular Cell Model , 2004, Circulation.

[52]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[53]  L. Sobrinho,et al.  A minimal mathematical model of calcium homeostasis. , 2002, The Journal of clinical endocrinology and metabolism.

[54]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[55]  Paul B Watkins,et al.  Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. , 2014, Biopharmaceutics & drug disposition.

[56]  H. Mistry,et al.  An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. , 2012, American journal of physiology. Heart and circulatory physiology.

[57]  Saskia Vosslamber,et al.  The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients , 2012, Arthritis Research & Therapy.

[58]  L. Sequist,et al.  246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[60]  Peter Junker,et al.  CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’ , 2014, Arthritis Research & Therapy.

[61]  R. Iyengar,et al.  Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.

[62]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[63]  Samik Ghosh,et al.  Connecting the dots: role of standardization and technology sharing in biological simulation. , 2010, Drug discovery today.

[64]  Henggui Zhang,et al.  The canine virtual ventricular wall: a platform for dissecting pharmacological effects on propagation and arrhythmogenesis. , 2008, Progress in biophysics and molecular biology.

[65]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[66]  Kapil Gadkar,et al.  Systems Modeling Applied to Candidate Biomarker Identification , 2011 .

[67]  P Vicini,et al.  A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model , 2014, CPT: pharmacometrics & systems pharmacology.

[68]  D. Fell,et al.  Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. , 2006, Bio Systems.

[69]  P Vicini,et al.  A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications , 2014, CPT: pharmacometrics & systems pharmacology.

[70]  Vincent Lemaire,et al.  Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.

[71]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[72]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[73]  A. Henney,et al.  The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[74]  Saroja Ramanujan,et al.  Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach[S] , 2016, Journal of Lipid Research.